Long-term follow-up of patients with hepatitis B e antigen negative chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 1, 2011, Pages 122-128

  Bekku, Dan ^a   Arai, Makoto ^a   Imazeki, Fumio ^a   Yonemitsu, Yutaka ^a   Kanda, Tatsuo ^a   Fujiwara, Keiichi ^a   Fukai, Kenichi ^a   Sato, Kenichi ^a   Itoga, Sakae ^a   Nomura, Fumio ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

HBe antibody; Hepatitis B virus; Long term follow up

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; THROMBOCYTE COUNT; VIRUS CARRIER;

EID: 78650408064     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06322.x     Document Type: Article

References (24)

1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 2008; 48: 335-52.
2. Di Marco V, Lo Iacono O, Camma C et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257-64.
3. Fattovich G, Olivari N, Pasino M et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.
4. Hoofnagle JH, Dusheiko GM, Seeff LB et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Intern. Med. 1981; 94: 744-8.
5. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. 1991; 114: 629-34.
6. Sumi H, Yokosuka O, Seki N et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37: 19-26.
7. Lin CL, Liao LY, Liu CJ et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007; 45: 1193-8.
8. Feld JJ, Ayers M, El-Ashry D et al. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007; 46: 1057-70.
9. Orito E, Ichida T, Sakugawa H et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34: 590-4.
10. Lai CL, Yuen MF. The natural history of chronic hepatitis B. J. Viral. Hepat. 2007; 14 (Suppl. 1): 6-10.
11. Murata K, Sugimoto K, Shiraki K et al. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection. World J. Gastroenterol. 2005; 11: 6848-52.
12. Pokorski RJ, Ohlmer U. Long-term morbidity and mortality in Chinese insurance applicants infected with the hepatitis B virus. J. Insur. Med. 2001; 33: 143-64.
13. Fujiwara K, Yokosuka O, Ehata T et al. The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers. Dig. Dis. Sci. 1998; 43: 368-76.
14. Kumar M, Sarin SK, Hissar S et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376-84.
15. Mels GC, Bellati G, Leandro G et al. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. Liver 1994; 14: 175-81.
16. Hoofnagle JH, Doo E, Liang TJ et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
17. Sanai FM, Benmousa A, Al-Hussaini H et al. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection? Liver Int. 2008; 28: 1011-18.
18. Lai M, Hyatt BJ, Nasser I et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J. Hepatol. 2007; 47: 760-7.
19. Villet S, Ollivet A, Pichoud C et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 2007; 46: 531-8.
20. Sa-nguanmoo P, Tangkijvanich P, Payungporn S et al. Dynamics of HBV DNA levels, HBV mutations and biochemical parameters during antiviral therapy in a patient with HBeAg-negative chronic hepatitis B. Asian Pac. J. Allergy Immunol. 2007; 25: 183-8.
21. Buster EH, van Erpecum KJ, Schalm SW et al. Treatment of chronic hepatitis B virus infection-Dutch national guidelines. Neth. J. Med. 2008; 66: 292-306.
22. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005; 128: 24-32.
23. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129: 1928-36.
24. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a metaanalysis. Gastroenterology 2007; 132: 1740-5.